Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Skinvisible signs licensing agreement for two acne products
Las Vegas - Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
Las Vegas
- Skinvisible, a research and development company focused on dermatology products, has signed a licensing agreement with Embil Pharmaceutical Co. for the right to develop and market two acne products, Earthtimes.org reports.
The two prescription anti-acne products are formulated with Invisicare,a patented polymer delivery technology, with the active ingredients Clindamycin HCL and Retinoic Acid.
Related Videos
Related Content
